Phillips A W, Woodrooffe J G, Courtenay J S, Whitaker A M, Thomas D, Woiwod A J
Transplantation. 1976 Aug;22(2):167-75. doi: 10.1097/00007890-197608000-00012.
Antibodies to cultured human lymphoblasts were raised in horses using a schedule employing both subcutaneous and intravenous routes of injection. Plasma from groups of horses was pooled and the IgG prepared from each pool was tested extensively for safety and immunosuppressive efficacy in vitro and in vivo. On the basis of the results of skin grafting in monkeys, only globulins derived from the first main bleeds were blended to produce a bulk for clinical use. One early pool of globulin was discarded because when undiluted, it was lethal in monkeys by the intravenous route, and another pool was discarded because it contained antibodies which bound to the glomerular basement membrane of rats. No signs of toxicity as judged by haematology, blood biochemistry, and histology were detected in monkeys receiving the clinical blend of globulin either subcutaneously or intravenously.
采用皮下和静脉注射相结合的方案，在马体内产生针对培养的人淋巴母细胞的抗体。将几组马的血浆汇集起来，从每个血浆池中制备的IgG在体外和体内进行了广泛的安全性和免疫抑制功效测试。根据猴子皮肤移植的结果，仅将首次主要采血所得的球蛋白混合，制成供临床使用的制剂。一个早期的球蛋白池被废弃，因为未稀释时，通过静脉途径对猴子具有致死性；另一个池也被废弃，因为它含有与大鼠肾小球基底膜结合的抗体。接受皮下或静脉注射球蛋白临床混合制剂的猴子，经血液学、血液生物化学和组织学检查，未发现毒性迹象。
